Results 181 to 190 of about 10,200,147 (283)

SAS/IML software usage and reference ; version 6

, 1990
SAS Institute
core  

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Molecular Characterization of DENV-1 Isolates From Pakistan Reveals Immunogenic Variability and Antiviral Potential of Phytochemicals Targeting the CprM Region. [PDF]

J Trop Med
Shah SA, Shahid SA, Rahman S, Ali M.
europepmc   +1 more source

SAS/ETS user's Guide Version 6, First Edition

, 1990
SAS Institute
core  

Standardization of measurement and reporting of medication adherence using the TEN‐SPIDERS tool for claims data

British Journal of Clinical Pharmacology, EarlyView.
This study provides the first open‐source tool to implement the complete TEN‐SPIDERS framework in linked datasets for the determination of the PDC for medication adherence. The TEN‐SPIDERS tool enables transparent, reproducible medication adherence research through automated reporting of all calculation parameters and flexible customization options ...
Adam C. Livori, Tzu‐Yung Kuo, Jenni Ilomäki, Monique F. Kilkenny, Stella Talic, Zanfina Ademi, J. Simon Bell, Jedidiah I. Morton, Lachlan L. Dalli   +8 more
wiley   +1 more source

SolvateIt: A Tool for Solvating Molecules. A Case Study of Phloroglucinol in Solution. [PDF]

J Comput Chem
Hernández-Urquieta Y, Moreno-Ceballos A, Castro ME, Melendez FJ.   +3 more
europepmc   +1 more source

29a-SA-6 時計の背理

Meeting Abstracts of the Physical Society of Japan, 1991
openaire   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

Short, animated storytelling social contact videos reduce addiction stigma in the UK, USA, and South Africa: a randomised controlled trial of 13,397 participants. [PDF]

EClinicalMedicine
Adam M, Rohr JK, Greuel M, Seeff M, Margulis E, Gates J, Klapow M, Liu S, Amsalem D, Bärnighausen T.   +9 more
europepmc   +1 more source